Editas Medicine (EDIT) Revenue (2015 - 2025)
Editas Medicine (EDIT) reported Revenue of $7.5 million for Q3 2025, up 12265.57% year-over-year from N/an in Q3 2024, and up 110.82% on a QoQ basis from $3.6 million in Q2 2025.
Editas Medicine (EDIT) has 11 years of Revenue data on file, last reported at $7.5 million in Q3 2025.
- Quarterly Revenue rose 12265.57% year-over-year to $7.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $46.4 million (down 24.9% YoY) and the FY2024 annual result came in at $32.3 million, down 58.64% from the prior year.
- Revenue grew to $7.5 million in Q3 2025 per EDIT's latest filing, from $3.6 million in the prior quarter.
- Across five years, Revenue topped out at $60.0 million in Q4 2023 and bottomed at $42000.0 in Q3 2022.
- The 5-year median for Revenue is $6.2 million (2021), against an average of $9.0 million.
- The widest annual swing landed in 2022, when Revenue slumped 99.32%; it then surged 12604.76% in 2023.
- Tracing EDIT's Revenue over 5 years: stood at $12.5 million in 2021, then sank by 47.58% to $6.5 million in 2022, then jumped by 818.74% to $60.0 million in 2023, then slumped by 49.03% to $30.6 million in 2024, then plunged by 75.35% to $7.5 million in 2025.
- Per Business Quant, the three latest EDIT Revenue figures stand at $7.5 million (Q3 2025), $3.6 million (Q2 2025), and $4.7 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | 3.58 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Dec 31, 2024 | 30.60 Mn |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 513,000.00 |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 60.05 Mn |
| Sep 30, 2023 | 5.34 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 9.85 Mn |
| Dec 31, 2022 | 6.54 Mn |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 6.36 Mn |
| Mar 31, 2022 | 6.77 Mn |
| Dec 31, 2021 | 12.47 Mn |
| Sep 30, 2021 | 6.20 Mn |
| Jun 30, 2021 | 379,000.00 |
| Mar 31, 2021 | 6.50 Mn |
| Dec 31, 2020 | 11.42 Mn |
| Sep 30, 2020 | 62.84 Mn |
| Jun 30, 2020 | 10.75 Mn |
| Mar 31, 2020 | 5.72 Mn |
| Dec 31, 2019 | 12.28 Mn |
| Sep 30, 2019 | 3.85 Mn |
| Jun 30, 2019 | 2.33 Mn |
| Mar 31, 2019 | 2.07 Mn |
| Dec 31, 2018 | 6.12 Mn |
| Sep 30, 2018 | 14.52 Mn |
| Jun 30, 2018 | 7.37 Mn |
| Mar 31, 2018 | 3.93 Mn |
| Dec 31, 2017 | 3.67 Mn |
| Sep 30, 2017 | 6.28 Mn |
| Jun 30, 2017 | 3.10 Mn |
| Mar 31, 2017 | 682,000.00 |
| Dec 31, 2016 | 898,000.00 |
| Sep 30, 2016 | 962,000.00 |
| Jun 30, 2016 | 3.39 Mn |
| Mar 31, 2016 | 805,000.00 |
| Dec 31, 2015 | 792,000.00 |
| Sep 30, 2015 | 670,000.00 |
| Jun 30, 2015 | 167,000.00 |